Alternative business models for drug discovery

  • Barry A. Bunin, Sean Ekins
  • Drug Discovery Today, August 2011, Elsevier
  • DOI: 10.1016/j.drudis.2011.06.012

Business models

What is it about?

A very short editorial suggesting how the whole company / academia / foundation /government drug discovery ecosystem could share molecules, models and data while at the same time retaining IP and selectively sharing others.

Why is it important?

Drug discovery is expensive, takes years and so any methods to try to speed it up or lower costs could be impactful. More collaboration and sharing could be an alternative and software can facilitate this.

Perspectives

Dr Sean Ekins
Collaborations in Chemistry

A very simple idea which built on the many technologies, databases and tools being developed at the time. I still don't think we have reached close to what is possible.

Read Publication

http://dx.doi.org/10.1016/j.drudis.2011.06.012

The following have contributed to this page: Dr Sean Ekins